On February 25, 2021, Optimi Health Corp. (CSE: OPTI) (“Optimi”) announced the closing of its oversubscribed initial public offering (the “Offering”). Pursuant to the Offering, the Company issued 27,600,000 units of the Company (the “Units”) at a price of $0.75 per Unit for aggregate gross proceeds to the Company of $20,700,000, which includes the full exercise of the over-allotment option. The common shares of the Company and the common share purchase warrants issued pursuant to the Offering commenced trading on February 25, 2021 on the Canadian Securities Exchange (the “Exchange”) under the symbol “OPTI” and “OPTI.WT”.
The Offering was led by Mackie Research Capital Corporation, as the lead agent and sole bookrunner, on behalf of a syndicate of agents, including Canaccord Genuity Corp. and Stifel Nicolaus Canada Inc.
Optimi is a developer of a vertically integrated functional mushroom brand focused on the health and wellness sector.
Miller Thomson advised Optimi on the Offering and list on the Exchange with a team led by Brian Fast and including Alex Lalka, Gosia Piasecka and Boris Degas (Capital Markets & Securities).
